Linch, A., Stavridi, F., Hook, J., Barbachano, Y., Gore, M., Kaye, S. B. (2008) Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer. GYNECOLOGIC ONCOLOGY, 109 (1). pp. 27-32. ISSN 0090-8258

Full text not available from this repository.

Abstract

Objectives. Weekly paclitaxel (WP) has been reported to have significant activity in patients with ovarian and primary peritoneal cancer patients while retaining a favorable toxicity profile. This study assessed the current usage of WP in routine clinical practice in a tertiary cancer center. Methods. We conducted a retrospective audit in 53 patients with recurrent ovarian or primary peritoneal cancer treated with WP (80-100 mg/m(2)) over a 2-year period (Nov 2003-Nov 2005). Toxicity was assessed using Common Toxicity Criteria, and response was evaluated using radiological and CA-125 criteria. Results. Patients had a median age of 69 (36-86) and previously received a median of 3 treatments (range 1-7). A median of 13 weekly doses of paclitaxel (range 1-39) were given. The response rate was 48% by radiological criteria and 69% by CA-125 assessment. Grade 3 toxicities were fatigue (13% of patients), peripheral neuropathy (11%) and neutropenia (8%) and there were no grade 4 toxicities. The median progression-free survival was 4. 8 months and median survival was 13. 5 months. There was no significant difference in efficacy between those 24 patients previously treated with taxanes (radiol. response 43%/CA-125 response 63%) and those 29 patients who had not received prior taxanes (radiol. response 52%/CA-125 response 76%). There was also no difference in efficacy for patients with platinum-free or treatment-free intervals of less than 6 months compared to 6 months or longer. Conclusions. WP is a well tolerated and active regimen in patients with pre-treated ovarian cancer and its use in recurrent disease is likely to increase. Further studies should aim to assess the importance of the "paclitaxel-free interval" in predicting response in relapsed disease, along similar lines as are now established for platinums. (c) 2008 Elsevier Inc. All rights reserved.

Item Type:	Article
Authors (ICR Faculty only):	Kaye, Stan and Gore, Martin
All Authors:	Linch, A., Stavridi, F., Hook, J., Barbachano, Y., Gore, M., Kaye, S. B.
Uncontrolled Keywords:	weekly paclitaxel; ovarian cancer; treatment-free interval SINGLE-AGENT PACLITAXEL; PHASE-II TRIALS; EVERY 3 WEEKS; RESISTANT OVARIAN; BREAST-CANCER; PLATINUM; CISPLATIN; CHEMOTHERAPY; RECURRENT; THERAPY
Research teams:	Clinical Units > Gynaecology Unit ICR divisions > Cancer Therapeutics > Medicine (Kaye Drug Development Unit) ICR divisions > Clinical Studies > Medicine (Kaye Drug Development Unit)
Depositing User:	Users 10 not found.
Date Deposited:	09 Jun 2008 14:27
Last Modified:	10 Feb 2010 11:50
URI:	http://publications.icr.ac.uk/id/eprint/6313

Actions (login required)

View Item